Comtech Telecommunications Stock To Go Ex-dividend Tomorrow (CMTL)

NEW YORK ( TheStreet) -- The ex-dividend date for Comtech Telecommunications Corporation (Nasdaq: CMTL) is tomorrow, October 19, 2011. Owners of shares as of market close today will be eligible for a dividend of 28 cents per share. At a price of $31.52 as of 9:30 a.m. ET, the dividend yield is 3.4%.

The average volume for Comtech Telecommunications has been 444,500 shares per day over the past 30 days. Comtech Telecommunications has a market cap of $761.1 million and is part of the technology sector and telecommunications industry. Shares are up 16.9% year to date as of the close of trading on Monday.

Comtech Telecommunications Corp. designs, develops, produces, and markets products, systems, and services for communications solutions in the United States and internationally. The company has a P/E ratio of 14.6, equal to the average telecommunications industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Comtech Telecommunications as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and unimpressive growth in net income. You can view the full Comtech Telecommunications Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus